Completed PHASE3 INTERVENTIONAL 1-arm NCT01230762

An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation

An Open Label Study of the Long-term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation

Sponsor: Alza Corporation, DE, USA

Conditions Ejaculation Erectile Dysfunction Sexual Dysfunction

Interventions dapoxetine

Updated 6 times since 2017 Last updated: May 18, 2011 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Ejaculation and Erectile Dysfunction and is currently completed. Alza Corporation, DE, USA leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alza Corporation, DE, USA

Data source: Alza Corporation, DE, USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.